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The gastrointestinal tract, in particular the colon, holds a complex community of
microorganisms, which are essential for maintaining homeostasis. However, in recent
years, many studies have implicated microbiota in the development of colorectal cancer 
(CRC), with this disease considered a major cause of death in the western world. The 
mechanisms underlying bacterial contribution in its development are complex and are
not yet fully understood. However, there is increasing evidence showing a connection
between intestinal microbiota and CRC. Intestinal microorganisms cause the onset and 
progression of CRC using different mechanisms, such as the induction of a chronic
inflammation state, the biosynthesis of genotoxins that interfere with cell cycle regulation, 
the production of toxic metabolites, or heterocyclic amine activation of pro-diet carcino-
genic compounds. Despite these advances, additional studies in humans and animal
models will further decipher the relationship between microbiota and CRC, and aid in
developing alternate therapies based on microbiota manipulation.
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COLOReCTAL CANCeR
According to the World Health Organization, cancer is a global health problem. In 2011, it was the 
leading cause of mortality positioned above stroke and coronary pathology. Approximately half of 
these deaths were due to lung, stomach, colon, and breast cancer.
Colorectal cancer (CRC) ranks third in incidence in men and second in women (1.4 million in 
2012). It stands at third place in mortality causing up to 690,000 deaths per year (1). Approximately 
75% of deaths from CRC occur in people over 65 years, with mortality higher in males. Analyzing age 
and sex together reveals that mortality in males is comparable to that of females who are 4–8 years 
older (2, 3). In Europe, CRC mortality is showing a downward trend in countries such as Austria, 
France, Ireland, Sweden, and Norway, unlike Eastern and Mediterranean countries such as Spain, 
Italy, and Greece (4). There are big differences in the incidence of CRC across countries, which are 
mainly attributed to diet.
Until recently, CRC was almost exclusively a public health issue in industrialized countries, but 
has now also become a problem in emerging countries due to economic growth (5). The adoption 
of a westernized lifestyle, increased consumption of red meat, high-calorie diets, and rising life 
expectancy in these countries have contributed to the increased incidence of CRC (6). Moreover, 
these countries have higher mortality due to a lack of healthcare resources (6).
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About 75% of CRC cases are not hereditary and occur 
spontaneously, while the remaining 25% of affected individuals 
have a family history, which shows the combined contribution of 
genetics and environmental factors. However, only between 5 and 
6% are due to main genetic alterations with a high penetrance (7). 
These facts justify the significant impact of environmental factors 
and lifestyle in the development of CRC. Numerous risk factors 
associated with CCR are analyzed: age, sex and race, diet habits, 
consumption of red meat, obesity, and toxic substances such as 
tobacco and alcohol (8, 9).
Determinant Factors of CRC
There are several environmental and individual-specific factors 
associated to CRC development. The evidence related to these 
factors is discussed below and the interactions between them are 
outlined in Figure 1.
The effect of diet is so important that in 1981 it was predicted 
that 90% of gastrointestinal cancers are due to differences in diet 
(10). A study published in the 90s focused on this aspect, and 
the rarity of CRC in the African race was related to the absence 
of consumption of aggressive factors, such as animal flesh and 
fat within this ethnic group (11). This is evident, for example, in 
immigration studies showing high rates of CRC in people who 
migrate from low-incidence countries to high-risk areas (12, 13). 
One example of this is that CRC incidence in Japanese people 
emigrating to the United States of America (USA) is similar to 
that of Caucasians living in the USA, and is three to four times 
FiGURe 1 | Factors involved in the development of colorectal cancer.
than that of Japanese people living in Japan. Similar results were 
found for native Africans and Afro-American people; although 
CRC incidence in the first group is much lower than that in the 
latter, mainly due to different environmental factors, especially 
diet habits (14). The important role of environmental factors is 
also evidenced in the age structure of CRC in developing coun-
tries. These countries have a high CRC incidence in young age 
ranges with lower levels in the oldest group. This suggests that 
recent lifestyle changes have increased the risk of young people to 
develop CRC. Such changes are related to diet habits, particularly 
increased fat and meat consumption (15, 16). There is evidence 
that red meat and animal fat are associated to an increased CRC 
risk (17).
A sedentary lifestyle, a Western diet rich in meat and fat and 
low in fiber, increases the risk of CRC. The absence of physical 
activity, increased caloric intake, and changes in eating patterns to 
a more westernized one were omnipresent settled in Eastern Asia, 
Europe, and North Africa, implying a parallel rise in obesity and 
in CRC incidence in these emerging countries (5, 18). Multiple 
studies support the idea of an increased risk of adenomas and 
CRC in patients with obesity and metabolic syndrome, which 
are associated to economic growth and globalization (19, 20). It 
seems that insulin-like growth factor, IGF-1, which is higher in 
obese people with insulin resistance, promotes cell growth and 
inhibits apoptosis pathways leading to carcinogenesis (21).
Toxic habits such as tobacco and alcohol consumption are also 
associated to an increase in the risk for CRC because they cause 
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chronic inflammation (22). Tobacco is particularly important 
since it also acts at other levels causing increased oxidative stress, 
genetic, and epigenetic alterations (19).
Genetic mutations, epigenetic changes and alterations in 
immunogenic signaling pathways associated and modified by the 
environment, are major contributors to CRC (23). The molecular 
mechanisms of interaction between the environment, genet-
ics, and carcinogenesis are very complex and are not yet fully 
understood. The genetic alterations that lead to the development 
of CRC have been extensively studied in recent decades. Current 
knowledge has mainly been obtained from studies on Western 
populations. Although the main signaling pathways are similar in 
developing countries, the spectrum of mutations may differ due 
to different environmental or genetic factors (14).
Epigenetic regulation plays a fundamental role in CRC initia-
tion and progression (23). Epigenetic alterations that involve DNA 
methylation, histone changes, or modification of antisense RNA 
can alter gene expression alone, or in combination with inherited 
or somatic mutations. For instance, alterations in methylation 
of certain CpG dinucleotides can inactivate the development of 
tumor suppressor genes (24). These epigenetic alterations can be 
strongly affected by diet habits or chronic alcohol consumption. 
Some food components cause changes in gene methylation (19).
There is a clear interaction between lifestyle, environmental 
factors, genetic, and epigenetic alterations. Certain lifestyles 
are associated with a CRC molecular subtype. Since obesity 
was associated with an increased risk of CRC, there have been 
many studies searching for the molecular pathways to prove this 
relationship. A recent meta-analysis demonstrated the inverse 
relationship between adiponectin levels and the risk of CRC (25). 
By contrast, leptin, which is present in high levels in obese people, 
is directly related to CRC risk. Another example is that the risk 
of developing tumors in subjects with the K-RAS mutation and 
p53 was lower in patients with increased physical activity. Even 
tobacco consumption was associated with an increased risk of 
microsatellite instability, BRAF mutations, and CIMP-positive 
tumors, which shows the relationship between tobacco and 
epigenetic alterations (26). Consumption of red meat and a high 
glycemic load, as in Western diet, was associated with the CRC-
p53 mutation (27).
Although there is evidence that diet influences the develop-
ment of CRC at the molecular level, it is not completely clear 
since the mechanism is highly complex, and requires the inter-
action of a large number of elements, as mentioned above. The 
interaction of dietetic factors in the gastrointestinal lumen and 
colonic epithelium is regulated by the genetic susceptibility of the 
individual. In addition, the microbiota is recently emerging as 
an increasingly important factor. It is believed that the intestinal 
component whose products determine the health of the colon 
and the individual, and interact with environmental factors and 
the genetics of the person (Figure 1).
COLONiC MiCROBiOTA
The emergence of molecular sequencing techniques is a major 
breakthrough for the identification of intestinal microorganisms 
that could not have been isolated and characterized by traditional 
culture methods (28–31). These molecular techniques are based 
on detecting differences in nucleotide sequences of various 
microbial genes. To do this, DNA is extracted from the sample, 
followed by amplification and sequencing of genes coding for the 
16S ribosomal RNA subunit. A recent development is “metagen-
omics,” where the genetic materials of samples of a particular eco-
logical niche are recovered and directly analyzed, thus obviating 
the need for isolating and culturing different member organisms 
(32). Furthermore, this technique not only has the advantage of 
phylogenetic characterization of a microbial community, but also 
provides information on the biological functions that are present 
in that community.
Colon Microbiota Composition
The gastrointestinal tract is the natural habitat of large, dynamic, 
and diverse populations of microorganisms, mainly bacteria that 
have adapted to life on mucosal surfaces or in the intestinal lumen 
(33, 34). The presence of each organism depends on the mor-
phological and physiological characteristics of respective regions 
of the digestive system (35). This microbiota grows in number 
and complexity as we move through the gastrointestinal tract. 
The large intestine is the main colonization niche in the human 
body. It is estimated that the colon houses about 1014 microbial 
cells, most of them bacteria. Bacteroidetes and Firmicutes are the 
dominant phyla in the large intestine, followed by Actinobacteria 
and Verrucomicrobia. The phylum Proteobacteria is also present, 
but to a lesser extent (36). Factors that facilitate bacterial growth 
in the colon are the increase in pH, reaching neutrality, and the 
reduction of both bile salt concentration and traces of pancreatic 
secretion. Furthermore, transit time in the colon is slow, providing 
microorganisms with the opportunity to proliferate, and ferment 
available substrates derived from diet or endogenous secretions 
(37, 38). The colon has a reductive environment devoid of oxygen. 
Thus, most microbial populations are strictly anaerobic. Within 
this microbiota, the Bacteroides genus is one of the most abun-
dant (39). Gram-positive non-spore-forming microorganisms 
such as Eubacterium, Bifidobacterium, Peptostreptococcus, and 
Ruminococcus are also dominant (39). Spore-forming Gram-
positive bacilli are mainly represented by the genus Clostridium. 
To a lesser extent, facultative anaerobes or aerotolerant ones such 
as enterobacteria, enterococci, lactobacilli, and streptococci, 
which are essential for microbial homeostasis, appear in the large 
intestine. Differences were observed in the composition between 
the microbiota that is present in the intestinal lumen, and the 
one associated with the mucosa, but their biological significance 
is still unclear (40, 41).
Microbiota Functional Capacity
The intestinal microbiota acts as a “metabolic organ” that inter-
acts with the human host and performs many essential functions 
required for the maintenance of human health (42). These meta-
bolic functions allow guests to use available energy sources such 
as carbohydrates and proteins. In return, the microbiota produce 
vitamins, synthesize amino acids, influence the absorption of 
ions, participate in the conversion of dietary polyphenolic com-
pounds, and are involved in the biotransformation of bile acids 
(43–45). Associated with these metabolic functions, the intestinal 
TABLe 1 | Gut bacteria associated with dysbiosis in CRC.
Microorganism Changes in 
microbiota
Sampling Reference
Fusobacterium ↑ Feces/Mucosa (56, 60, 70)
Enterococcaceae ↑ Feces (60, 71)
Campylobacter ↑ Feces (60)
Erysipelotrichaceae ↑ Feces (60, 72)
Collinsella ↑ Feces (60)
Peptostreptococcus ↑ Feces/Mucosa (56, 60)
Anaerotruncus ↑ Feces (60)
Faecalibacterium ↓ Feces/Mucosa (56, 60)
Roseburia ↓ Feces (56, 60)
Porphyromonas ↑ Mucosa (56)
Mogibacterium ↑ Mucosa (56)
Blautia ↓ Mucosa (56)
Bifidobacterium ↓ Mucosa (56, 73, 74)
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microbiota is essential for the development of the immune sys-
tem, helping it maintain the function of the intestinal barrier and 
assisting in an adequate immune response to pathogens (46–48). 
This symbiotic relationship with the host is key for maintaining 
the balance of the gut microbiota in the intestine. A change in 
that balance (dysbiosis) under abnormal conditions may cause 
adverse consequences for the host. This intestinal dysbiosis may 
be associated with the overgrowth of opportunistic pathogens 
that are normally inhibited by commensal bacteria (49). It has 
been described in inflammatory digestive diseases (50–52), obe-
sity (53–55), colorectal adenomas, and cancer (56–60).
MiCROBiOTA AND COLON CANCeR
Colon cancer is the result of a multifactorial process whose 
progression is associated with the gradual accumulation of 
genetic and epigenetic mutations. In more than 90% of these 
cases, it is sporadic and develops gradually with the appearance 
of adenomatous polyps in the epithelium, leading to an invasive 
carcinoma. It is a slow process, which can last up to 10  years, 
depending on mutation frequency (61). Besides genetic factors, 
environmental factors associated with the onset of colon cancer, 
such as chronic inflammation or diet habits, are also implicated 
(62, 63). Nevertheless, in recent years studies have implicated the 
intestinal microbiota in the development of this disease (64–66).
intestinal Dysbiosis and CRC
Initially, colon cancer was associated with certain pathogenic 
species such as Streptococcus gallolyticus, Helicobacter pylori, or 
Escherichia coli (67, 68). However, a number of studies over the 
past decade maintain that there are multiple bacterial species that 
contribute to CRC. Alterations in the composition, distribution, 
and metabolism of the microbiota in the colon may cause changes 
in homeostasis resulting in the onset of inflammation, dysplasia, 
and cancer (69). The main gut bacteria implicated in dysbiosis, 
found in several studies, are listed in the Table 1 and discussed 
below.
Using next generation sequencing techniques, several studies 
have been conducted to compare fecal samples and luminal intes-
tinal microbiota of CRC patients and healthy individuals (40, 56, 
60, 66). These studies have shown greater microbial richness in 
patients with rectal adenomas compared to control individuals, 
where Pseudomonas, Helicobacter, and Acinetobacter genera 
appear, suggesting that these pathogens can disrupt the intestinal 
environment, for instance, by causing pH changes, described in 
association with Helicobacter (59). Increases in Fusobacterium, 
Enterococcaceae, Campylobacter, Erysipelotrichaceae, Collinsella, 
Peptostreptococcus, and Anaerotruncus have also been seen 
in fecal samples from CRC patients compared to healthy 
control individuals, opposite to a decrease of cluster IV and 
XIV Clostridium members, such as Faecalibacterium praus-
nitzii and Roseburia, both butyrate-producing bacteria. CRC 
patients showed an increase of Porphyromonas, Fusobacterium, 
Peptostreptococcus, and Mogibacterium in the intestinal mucosa, 
while Faecalibacterium, Blautia, and Bifidobacterium appeared 
diminished. Therefore, microbiota associated to sick patients is 
enriched with pro-inflammatory opportunistic pathogens such 
as Fusobacterium, Campylobacter, and Enterococcaceae (70, 71), 
as well as, microorganisms commonly associated with metabolic 
disorders, such as Erysipelotrichaceae (72). By contrast, strategic 
patterns that preserve microbial intestinal homeostasis are 
decreased, as in the case of butyrate-producing bacteria and 
bifidobacteria (73, 74). Overall, these data reflect the ecosys-
tem of the intestinal microbiota of patients with CRC, i.e., a 
pro-inflammatory profile that can modify the existing mutual 
relationship between the microbiota and the host, eventually 
lead to a state of disease (65). An enrichment of microorganisms 
specifically localized to the tumor area was also seen by com-
parative analysis between the existing microbiota in cancerous 
mucosal tissues and surrounding tissues (56, 66, 75, 76). Burns 
et al. (75), in addition to showing increased microbial diversity 
in the tumor area, also described an enrichment of virulence-
associated bacterial genes in the tumor microenvironment, sup-
porting the hypothesis that the microbiome plays an active role 
in CRC development and/or progression. On the other hand, 
it has also been demonstrated for the first time, that bacterial 
biofilms are associated with CRCs. These bacterial biofilms were 
associated with diminished colonic epithelial cell E-cadherin 
and enhanced epithelial cell IL-6 and STAT3 activation, as well 
as increased crypt epithelial cell proliferation, in normal colon 
mucosa. The risk of developing CRC is higher in patients with 
biofilms compared to those without them (77).
However, these studies do not reflect whether intestinal dysbi-
osis is a cause or consequence of the disease. Nor do they provide 
information about the mechanisms through which the intestinal 
microbiota influence the development of CRC, or more precisely, 
the trigger that gives the microbiota a carcinogenic profile. In 
order to answer this question, the role that microorganisms play at 
the beginning of CRC was explored. Tjalsma et al. (78) proposed 
a dynamic model that explains how the microbiota is involved in 
the onset and progression of CRC, which he called the “bacterial 
driver-passenger.” According to this model, certain populations 
of bacteria (drivers) with pro-carcinogenic features are able to 
initiate the development of the disease, by damaging the DNA in 
the intestinal epithelium. Following tumorigenesis initiation, an 
alteration of the intestinal environment occurs, resulting in the 
overgrowth of opportunistic bacteria (passengers) and a decrease 
FiGURe 2 | Mechanisms possibly involved in microbial colorectal cancer promotion and the dynamic model “bacterial driver-passenger.” Gut 
microorganisms may promote colorectal cancer onset and progression by different processes, such as the induction of a chronic inflammatory state, the biosynthesis of 
genotoxins interfering with the cell cycle regulation or directly damaging DNA, or the production of toxic metabolites. According to the model, “bacterial driver-passenger” 
occurs a change in the composition of the gut microbiota. At the beginning of colorectal cancer progression, driver bacteria are able to initiate the development of the 
disease. Following tumorigenesis initiation, an alteration of the environment occurs, resulting in the overgrowth of passenger bacteria. ROS, reactive oxygen species; 
STAT3, signal transducer and activator of transcription 3; H2S, hydrogen sulfide.
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in pioneer strains. Passenger bacteria are always autochthonous 
members of the gut microbial community, are relatively poor 
colonizers of a healthy intestinal tract, and show a competitive 
advantage in the tumor microenvironment, since they are capable 
of promoting tumor progression. For instance, nutrients and co-
factors specific to the tumor microenvironment – such as reactive 
oxygen species – can be selectively utilized by specific bacterial 
passengers. However, in contrast to drivers, which are always pro-
carcinogenic, passenger bacteria can be either pro-carcinogenic 
or protective, depending on the microorganism (78).
Possible Mechanisms of Action of 
intestinal Microbiota in CRC Pathogenesis
Figure  2 contains the factors involved in CRC development 
with possible mechanisms associated to the role of intestinal 
microbiota in tumor pathogenesis. In recent years, it has been 
observed that intestinal microorganisms can promote the onset 
and progression of CRC by different processes, such as the induc-
tion of a chronic inflammation state, genotoxin biosynthesis that 
interfere with cell cycle regulation, toxic metabolite production, 
or heterocyclic amine activation of pro-diet carcinogenic 
compounds (65). Chronic inflammation is associated with a 
high risk of developing cancer and does so by inducing muta-
tions, inhibiting apoptosis or stimulating angiogenesis and cell 
proliferation (79, 80). An imbalance of microbiota in favor of 
opportunistic pathogens contributes to higher mucosa perme-
ability, bacterial translocation, and the activation of components 
of both the innate and adaptive immune systems, resulting in 
chronic inflammation (81). The activation of the innate immune 
system by commensal bacteria results in an increased release of 
pro-inflammatory cytokines by macrophages, dendritic cells, and 
“natural killer” cells, such as IL-12, IL-23, TNF-α, and INFγ, with 
subsequent activation of cells of the adaptive immune system, 
including lymphocytes, both T and B cells, and various inflam-
matory mediators (48). One of the major consequences of this 
inflammatory response to commensal bacteria is the activation of 
transcription factors of specific key cellular signaling pathways, 
such as NF-κB and STAT3, in epithelial cells (82–85), and the 
generation of reactive oxygen and nitrogen species, leading to 
oxidative stress, DNA damage, aberrant proliferation, and, finally, 
the development of colorectal adenomas and cancer. It has been 
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shown that colonization of germ-free animals with Enterococcus 
faecalis and Bacteroides vulgatus leads to the activation of NF-κB 
signaling pathways in epithelial cells (86). Colonization of germ-
free mice with microbiota from tumor-bearing mice significantly 
increased tumorigenesis in the colon, compared to animals 
colonized with healthy gut microbiota (87). Whereas coloniza-
tion of germ-free mice with human microbiota (CRC patients 
and healthy individuals) suggests that the initial structure of 
the microbiome determines susceptibility to tumorigenesis in 
the colon (88). Therefore, to date, these studies suggest that the 
alteration of normal homeostasis between host and microbiota is 
crucial for inflammation and consequently a number of changes 
occur that lead to colon carcinogenesis. Furthermore, it has been 
found that colonic polyposis is associated with high densities of 
microorganisms accumulated inside polyps, which trigger local 
inflammatory response. The inflammatory responses, as well as 
microbial density and polyp growth, can be suppressed by IL-10, 
specifically derived from T and T-regs cells (89).
Intestinal microbiota has also been associated with CRC 
development, due to toxic or genotoxic bacterial metabolite 
production that may lead to mutations by binding to specific cell 
surface receptors and affecting intracellular signal transduction 
(90). These toxins affect many key eukaryotic processes, such as 
cell signaling, and in some cases, can directly attack the genome, 
damaging DNA and undertake an enzymatic attack or an indirect 
attack causing an inflammatory reaction resulting in the release of 
free radicals. It has also been seen that they can affect DNA repair 
mechanisms (65). For instance, Bacteroides fragilis enterotoxigenic 
strains can colonize the human mucosa in an asymptomatic way, 
but in some cases they release the B. fragilis toxin (BFT) that can 
cause inflammatory diarrhea. BFT is a zinc-dependent metallo-
protease that quickly alters the structure and function of epithelial 
cells of the colon, including the breaking of the tumor suppressor 
protein, E-cadherin (91–93). E-cadherin is a calcium dependent 
cell–cell adhesion molecule with pivotal roles in epithelial cell 
behavior, tissue formation, and cancer suppression (94). The loss 
of this protein increases the permeability of polarized epithelial 
cells in the colon, this being one of the first tumor development 
steps (95). BFT also activates the transcription factor NF-κB 
resulting in the release of cytokines that contribute to mucosa 
inflammation (96). However, although BFT is considered one of 
the main toxins in CRC development, recent studies have shown 
that toxins that are most actively transcribed in tumor tissues of 
CRC patients are derived from E. coli, Salmonella enterica, and 
Shigella flexneri. This suggests the strong involvement of entero-
bacterial toxins in tumorigenesis (97). Certain commensal E. coli 
strains are able to produce colibactin toxin directly in the colon. 
This toxin causes double-strand breaks in the DNA of colon cells. 
Cellular repair systems fail to restore these DNA lesions, which 
result in an accumulation of chromosomal anomalies and, thus, 
mutations leading to tumorigenesis (98).
The effect of diet on colorectal adenomas and cancer has been 
studied in detail. Diet mainly affects the composition and activity 
of intestinal bacteria (99). Therefore, the connection between 
diet and CRC can be partly explained, from intestinal microbiota 
activities. Fermentation of complex carbohydrates by colonic 
bacteria releases SCFAs, such as butyrate, which are an energy 
source for colonocytes (100) and are demonstrated to have a 
protective role preventing the development of CRC (101–103). 
Butyrate promotes many of the large intestine functions, such as 
colon motility, improving visceral blood flow, and preventing the 
overgrowth of pathogens (104–107). It also reduces inflamma-
tion, induces apoptosis, and inhibits tumor cell progression (104, 
105, 108, 109). Several studies showed that the presence of fiber in 
the diet influences SCFA production (110). Therefore, a fiber-rich 
diet results in a significant increase in SCFAs, with a consequent 
reduction in intestinal pH, which favors colonic fermentation, 
prevents pathogen colonization, and decreases carcinogen 
absorption (106), thus reducing CRC risk (48).
It has been seen that gut bacteria contribute to nutrient metabo-
lism and produce small molecules, which may contribute to the 
development of neoplastic cells in the large bowel, since metabolic 
differences are seen during the analysis of rectal mucosa biopsies 
from individuals with and without adenomas. Nugent et al. (58) 
described the existence of around 23 metabolites in adenomas, some 
of them with an inflammatory nature, such as PGE2, and a decrease 
in antioxidant metabolites, such as, 5-oxoproline and diketogulonic 
acid. Several microbial metabolites have been identified as potential 
carcinogens, particularly secondary bile acids that were detected at 
high levels in fecal samples from CRC patients (111).
The intestinal microbiota plays an important role in the 
metabolism of bile acids, mainly in the 7α-hydroxylation process, 
where cholic acid is converted into deoxycholic acid while cheno-
deoxycholic acid turns into lithocholic acid. This transformation 
increases the hydrophilicity of these secondary bile acids (112). It 
was shown that deoxycholic acid damages intestinal tract mucosa 
and contributes to an increase in reactive oxygen species, damag-
ing DNA, generating genomic instability, and benefiting tumor 
growth – a process that could be key in the effect of bile acids 
on colon carcinogenesis (113). Secondary bile acids may also 
influence CRC by supporting of apoptosis-resistant cells or by 
interacting with important secondary messengers of the signaling 
system that are activated in CRC (114).
Some other metabolites that may also be involved in CRC 
development are protein fermentation-derived products (65). 
If an increase in protein intake occurs, there is an increase of 
waste in the colon, such as sulfide, nitrate, ammonium, amines, 
branched-chain amino acids, and H2S. Such waste resulting from 
protein digestion can stimulate the growth of sulfate-reducing 
bacteria, such as Desulfovibrio and Desulfomonas spp. (115). H2S, 
an end product of protein metabolism, was shown to be pro-
inflammatory and genotoxic (116). In addition, CRC patients 
have a higher concentration of H2S compared to healthy subjects 
(117), and their colons have decreased ability to detoxify, thus 
promoting genotoxic effects (118, 119). Another bacterial sub-
group, which includes several species of Bacteroides genus and 
some Firmicutes, is responsible for the fermentation of aromatic 
amino acids leading to potentially bioactive products, such as 
phenylacetic acid, phenols, indoles, and p-cresol. Some of these 
nitrogen products, particularly N-nitrous compounds (NOCs), 
have a potential role in causing cancer and exert their carcinogenic 
effect by alkylating DNA, leading to mutations. Consumption 
of NOCs in the diet is positively correlated with CRC (120), 
although these compounds may also be endogenously formed in 
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the stomach or from nitrosation of amines that are derived from 
proteins fermented by existing microbiota in the large intestine. 
An increase in NOCs in the feces of individuals on a protein-rich 
diet has been described (121). Therefore, higher consumption of 
red meat or processed meat, compared to fruits and vegetables, 
is associated with an outgrowth of bacteria that might contribute 
to a more hostile gut environment, and is generally considered a 
risk factor in the development of colorectal adenomas and can-
cer (122–125). Bacteria metabolize meat proteins and produce 
nitrosamines, which are considered promoters of colon tumors 
that can be seen in animal models (126).
CONCLUSiONS AND FUTURe 
GUiDeLiNeS
All above studies suggest that different microbial metabolites 
generated from the metabolism of carbohydrates, proteins, and 
lipids could contribute to colorectal carcinogenesis through 
different mechanisms. It is necessary to undertake additional 
studies, in humans and animal models, to decode and under-
stand the mechanisms underlying the interaction between 
diet, microbiota, and CRC. This will allow us to manipulate the 
microbiota to prevent or treat CRC (48). The use of probiotics is 
an alternative that has increased in popularity in recent years. 
A large number of studies conducted both in  vitro and in 
animal models showed that consumption of probiotics could 
prevent CRC. In addition, treatment with probiotics increased 
the density and diversity of mucosal microbes, and altered the 
mucosa-associated microbiota in patients with CRC (127). It 
has also been seen that its use in CRC patients can influence 
innate immune system routes, and modulate apoptosis, reduce 
oxidative stress, and change intestinal bacteria composition and 
metabolism (69, 128). Although a number of laboratory studies 
exist, only a limited number of clinical trials have evaluated the 
potential role of probiotics in suppressing CRC. Probiotics most 
frequently used in clinical trials are species of the Lactobacillus 
genus. For example, it was found that Lactobacillus johnsonii 
reduced the concentration of intestinal Enterobacteriaceae and 
modulated the immune response in CRC patients (129). Other 
research showed that Lactobacillus casei reduced the growth 
of colorectal tumors in patients after 2–4  years of treatment. 
However, these trials are limited by patient numbers and their 
short lengths (130). Thus, it is necessary to perform additional 
studies to further support the clinical use of probiotics as pre-
ventative treatment for CRC.
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